2PHARMA HOLDING: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
2PHARMA HOLDING
Largest movements
- Receivables within one year -€38,504
no longer reported in 2025 (was €38,504)
of which Other amounts receivable: -€38,383
- Other debts -€36,231
down €36,231 (-1.9%), from €1.9m to €1.8m
- Gross operating margin +€924
up €924 (+33.9%), from -€2,727 to -€1,803
- Financial income -€569
down €569 (-61.9%), from €919 to €350
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,905,478 | €1,866,314 | -€39,164 | -2.1% |
| Fixed assets | 21/28 | €1,866,000 | €1,866,000 | = | 0.0% |
| Financial fixed assets | 28 | €1,866,000 | €1,866,000 | = | 0.0% |
| Current assets | 29/58 | €39,478 | €314 | -€39,164 | -99.2% |
| Amounts receivable within one year | 40/41 | €38,504 | - | -€38,504 | |
| Trade receivables | 40 | €120 | - | -€120 | |
| Other amounts receivable | 41 | €38,383 | - | -€38,383 | |
| Deferred charges and accrued income | 490/1 | €974 | €314 | -€660 | -67.8% |
| Total equity and liabilities | 10/49 | €1,905,478 | €1,866,314 | -€39,164 | -2.1% |
| Equity | 10/15 | €37,685 | €34,480 | -€3,205 | -8.5% |
| Contributions | 10/11 | €61,500 | €61,500 | = | 0.0% |
| Capital | 10 | €61,500 | €61,500 | = | 0.0% |
| Issued capital | 100 | €61,500 | €61,500 | = | 0.0% |
| Reserves | 13 | €2,471 | €2,471 | = | 0.0% |
| Non-distributable reserves | 130/1 | €2,471 | €2,471 | = | 0.0% |
| Legal reserve | 130 | €2,471 | €2,471 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€26,286 | -€29,491 | -€3,205 | -12.2% |
| Amounts payable | 17/49 | €1,867,793 | €1,831,834 | -€35,959 | -1.9% |
| Amounts payable within one year | 42/48 | €1,867,793 | €1,831,834 | -€35,959 | -1.9% |
| Trade debts | 44 | €2,793 | €3,065 | +€273 | +9.8% |
| Suppliers | 440/4 | €2,793 | €3,065 | +€273 | +9.8% |
| Other amounts payable | 47/48 | €1,865,000 | €1,828,769 | -€36,231 | -1.9% |
| Other operating charges | 640/8 | €1,162 | €1,143 | -€20 | -1.7% |
| Non-recurring operating charges | 66A | - | €103 | +€103 | |
| Gross operating margin | 9900 | -€2,727 | -€1,803 | +€924 | +33.9% |
| Operating profit (loss) | 9901 | -€3,889 | -€3,048 | +€841 | +21.6% |
| Financial income | 75/76B | €919 | €350 | -€569 | -61.9% |
| Recurring financial income | 75 | €919 | €350 | -€569 | -61.9% |
| Financial charges | 65/66B | €495 | €507 | +€12 | +2.5% |
| Recurring financial charges | 65 | €495 | €507 | +€12 | +2.5% |
| Profit (loss) for the period before taxes | 9903 | -€3,465 | -€3,205 | +€260 | +7.5% |
| Profit (loss) for the period | 9904 | -€3,465 | -€3,205 | +€260 | +7.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,465 | -€3,205 | +€260 | +7.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 15 October 2026 via checked.be.